Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
189P - Are pretreatment neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and advanced lung cancer inflamation index (ALI) levels useful in predicting the outcomes of patients with advanced non-small cell lung cancer? (ID 429)
12:30 - 13:00 | Presenting Author(s): B. Komurcuoglu
Systemic inflammation is both involved in the pathogenesis of cancer and can be activated by oncogenic changes in cancer cells. Inflammation parameters in cancer patients can increase due to different reasons such as cachexia, anorexia, pain. Systemic inflammatory markers in cancer are easily calculated using routine laboratory data, which can be used to identify high-risk patients, and predict the progression of the disease.
Between January 2013 and December 2015, 115 cases with advanced lung cancer diagnosed at our hospital were retrospectively reviewed. The cases were staged according to TNM 7. NLR (neutrophil lymphocyte ratio), PLR (platelet lymphocyte ratio) and BMI (body mass index) and ALI (advanced lung cancer inflammation index) values of patients were calculated. ALI was calculated as (BMI x Alb/NLR). For ALI 18, NLR 5, PLR 250 cut off levels were accepted. These values were compared with progression-free survival and overall survival of patients.
Our study of 115 patients, 15 (13.04%) were female and 100 (86.96%) were male. The mean age of the cases was 61.51 + 9.69 (min 41, max 83). 38 patients were stage 3B and 77 patients were stage 4. Patients histopathologic patterns were 43 adenocarcinomas, 37 squamous cell, 27 small cell and 8 non-small cell lung cancer. 19 of the patients were palliatively treated according to performance status and additional chronic illnesses. 73 cases were chemotherapy (CT), 7 cases were CRT, 13 cases were consecutive CT-RT, 1 case was operated on after induction, 2 cases only thoracic RT was applied. There were NLR <5.00 77 (67%) and >5.00 38 (33%) patients for overall survival (OS). The average time for OS under NLR 5.00 was 9.67 months, 5.95 per month above 5.00. A statistically significant difference was observed in the NLR value for the time period up to the OS (p:0.026; p < 0.05). OS was observed in 44 (38%) of the patients under levels of 18.00 ALI, and 71 (62%) of patients over 18.00 ALI. The average time for OS under ALI 18.00 was 4.24 months versus 10.13 months for the others. A statistically significant difference was observed between the ALI value and the OS (p:0.000; p < 0.05). There was no significant difference between PFS and OS for PLR value (p > 0.05).
We found that the NLR and ALI values at diagnosis were related to survival in patients with advanced lung cancer, and that the cut-off values indicated may be useful in predicting the survival and prognosis of the patient.
Clinical trial identification:
Legal entity responsible for the study:
Izmir Dr. Suat Seren Education Hospital Etic Comitty
Has not received any funding
All authors have declared no conflicts of interest.